Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Sarcoma 1

Conditions

Neoplasms 3

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × fosaprepitant × Tumor-Agnostic × Clear all
NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
690 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT04508400 2024-01-09

Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients

Sun Yat-sen University

Phase 2 Completed
108 enrolled
Tumor-Agnostic

Neoplasms

NCT05755659 2023-03-06

COSEFDIP

Xijing Hospital

Phase NA Unknown
3,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡